

## **Rating: Subscribe for Long Term**

### **Issue Offer**

Fresh Issue of equity shares worth INR 2,800 Mn and an Offer for Sale of 24,000,900 Equity shares.

| Issue Summary               |                  |
|-----------------------------|------------------|
| Price Band (INR)            | 516-542          |
| Face Value (INR)            | 10               |
| Implied Market Cap (INR Mn) | 55,010           |
| Market Lot                  | 27               |
| Issue Opens on              | April 27th, 2022 |
| Issue Close on              | April 29th, 2022 |
| No. of share pre-issue      | 96,334,008       |
| No. of share post issue     | 101,500,060      |
| Listing                     | NSE / BSE        |
| Issue Break-up (%)          |                  |
| QIB Portion                 | 50               |
| NIB Portion                 | 15               |
| Retail Portion              | 35               |

# **Book Running Lead Managers**

J.P. Morgan

IIFL Securities Ltd.

#### Registrar

Kfin Technologies Pvt. Ltd.

| Shareholding Pattern       |           |            |  |
|----------------------------|-----------|------------|--|
|                            | Pre-Issue | Post-Issue |  |
| Promoters & Promoter Group | 62.19%    | 49.83%     |  |
| Public                     | 37.81%    | 50.17%     |  |

### Objects of the issue

➤ Early redemption of NCDs issued by the company

➤ Capital expenditure towards setting up of new hospitals and purchase of medical equipments for new hospitals ➤ General corporate purposes

#### Abhishek Jain

abhishek.jain@arihantcapital.com 022-422548871

#### **Company Profile:**

Rainbow Children's Medicare Ltd. is a leading multi-specialty pediatric, obstetrics and gynecology hospital chain in India. It operates 14 hospitals and three clinics in six cities, with a total bed capacity of 1,500 beds, as of September 30, 2021. Its core specialties are pediatrics, which includes newborn and pediatric intensive care, pediatric multi-specialty services, pediatric quaternary care (including multi organ transplants); and obstetrics and gynecology, which includes normal and complex obstetric care, multidisciplinary fetal care, perinatal genetic and fertility care. Five of its hospitals are accredited by National Accreditation Board for Hospitals & Healthcare Providers (NABH) and three are certified by EDGE (Excellence in Design for Greater Efficiencies). It follows a hub-and-spoke model in Hyderabad, with Banjara Hills hospital (comprising 250 beds) being the hub and four spokes at four locations in Hyderabad, namely Secunderabad, LB Nagar, Kondapur and Hydernagar. As of September 30, 2021, the company had 602 full time doctors and 1,686 part time/visiting doctors.

### Investment Rationale:

Expanding hospital facilities will facilitate future growth: Rainbow Children's Medicare will utilize about INR 1,000 Mn from the IPO (Initial Public Offering) proceed towards setting up new hospitals and expanding the hospital network in India. It will deploy additional INR 700 Mn from the IPO proceeds towards purchase of medical equipments for new hospitals. These will include critical care equipment, surgical equipment, radiology equipment and medical furniture. The Board of Directors have already approved the amount for capital expenditure. The company has received quotations from various vendors for the proposed capex for the purchase of equipments.

Deleveraging to strengthen balance sheet: The company has issued non-convertible debentures (NCD) and the total outstanding NCDs aggregate to INR 400 Mn, as of September 30, 2021. It is looking to redeem the NCDs early to the tune of INR 400 Mn. This will help the company to reduce its outstanding indebtedness and debt servicing cost. Post the improvement of its leverage ratio, the company can benefit by raising debt at a lower rate of interest. Overall, the finance cost of the company will reduce and will directly support the bottom-line.

Operationally efficient through hub and spoke model: It follows a hub-and-spoke model in Hyderabad, with Banjara Hills Hospital being the hub and four spokes at four locations in Hyderabad, namely Secunderabad, LB Nagar, Kondapur and Hydernagar. At the hub hospital, it provides comprehensive outpatient and inpatient care with a focus on tertiary and quaternary care, and at the spokes, it provides secondary care in pediatrics, obstetrics and gynecology and emergency services. Under this model, the super-specialty doctors based at the hub hospital are able to reach out to a larger community and cover a larger catchment area. This model has enabled the company to evolve from a single secondary care hospital in Hyderabad to six hospitals in the city and an established provider of tertiary and quaternary care services at the hub hospitals.

Valuation and Outlook: At the upper price band of INR 542 per share, the company is valued at a TTM P/E multiple of 52x based on TTM EPS of INR 10.4. The hospital network is profitable and revenues from operations have surpassed the pre-Covid levels. The top-line has increased at a CAGR of 9.5% between FY19 and FY21. The future growth will be driven by facility expansion through new hospitals, better operational efficiency and overall buoyancy in the hospital sector post the pandemic. Also, deleveraging will further strengthen the balance sheet to support long term growth of the company. Long term investors can subscribe to the issue of Rainbow Children's Medicare Ltd.

#### **About the Business**

- > Based in South India, Rainbow Children's Medicare Ltd. is a major hospital network, mostly dedicated to pediatric care.
- > It has a total of 14 hospitals and three clinics. These include 1 hospital and 1 clinic at Visakhapatnam, 1 hospital and 1 clinic at Vijayawada, 6 hospitals and 1 clinic at Hyderabad, 3 hospitals at Bengaluru and 1 hospital at Chennai.
- Its specialties are classified into 2 categories:
  - *Pediatrics,* including newborn and pediatric intensive care, pediatric multi-specialty care services and pediatric quaternary care, where it also performs multi-organ transplants in children.
  - Obstetrics and gynecology, including normal and complex obstetric care, multi-disciplinary fetal care and perinatal genetic care, as well as fertility treatment, where it offers a wide range of assisted reproduction treatments.

## **Key Risks**

- Although, the company has hospital facilities in about 5 cities, the major revenues are concentrated in Hyderabad and Bengaluru. Volumes at the hospitals located in these two cities contributed about 77.7% of the overall volumes for six months ending September 2021. Any material impact in these hospital facilities can affect the financial performance of the company.
- > The different specialties of the hospital chain include secondary pediatric care, tertiary pediatric care, quaternary pediatric care and women care. Out of these, the secondary pediatric care accounts for the largest portion of the revenues. Slowdown in this segment can materially affect the financial performance of the company.
- > The hospital industry is part of the service sector and largely depends on the quality of workforce and attrition rate. The operations of Rainbow Childrens Medicare depend upon its doctors and the nursing staff. Higher attrition rate or unable to retain key talent can negatively affect the operational performance of the hospital network.

## **Peer Comparison:**

| Company                                    | Revenue (INR<br>Mn, FY21) | Face Value<br>(INR) | EPS (INR,<br>FY21) | P/E | RoNW<br>(FY21) | NAV (INR,<br>FY21) |
|--|---------------------------|---------------------|--------------------|-----|----------------|--------------------|
| Apollo Hospital Enterprise Ltd.            | 106,050                   | 5                   | 11                 | 435 | 8.9%           | 48.8               |
| Fortis Healthcare Ltd.                     | 40,767                    | 10                  | -1                 | NA  | -0.8%          | 81.1               |
| Narayana Hrudalaya Ltd.                    | 26,105                    | 10                  | -1                 | NA  | -1.5%          | 54.8               |
| Max Healthcare Ltd.                        | 26,194                    | 10                  | -2                 | NA  | -2.5%          | 58.4               |
| Krishna Institute of Medical Sciences Ltd. | 13,401                    | 10                  | 26                 | 51  | 23.7%          | 111.3              |

### Management

| Key Person           | Description  |
|----------------------|--|
| Dr. Ramesh Kancharla | He is the Chairman and Managing Director of the company. He holds a Bachelor of Medicine and Bachelor of       |
|                      | Surgery (MBBS) from Sri Venkateswara University and a Doctor in Medicine (MD) in paediatrics from              |
|                      | Mangalore University. He has over 23 years of experience with Rainbow Children's Medicare Ltd.                 |
| R Gowrisankar        | He is the Chief Financial Officer of the Company. He has been associated with the company for over 7 years     |
|                      | and in the current position since June 14, 2019. He has over 21 years of professional experience and has been  |
|                      | previously associated with Apollo Hospitals Enterprise Ltd., MNE Technologies Pvt. Ltd., Takshasila Healthcare |
|                      | and Research Service Private Ltd., Manipal Health Systems Pvt. Ltd., Manipal Health Enterprises Pvt. Ltd.,     |
|                      | Vanpic Ports Pvt. Ltd., Yashomati Hospitals Pvt. Ltd. and Yashoda HealthCare Services Pvt. Ltd.                |
| Mahesh Madduri       | He is the Head of Strategy of the company. He has been associated with the company since September 1,          |
|                      | 2021. He holds a MS Industrial Administration degree from Carnegie Mellon University, Pittsburgh               |
|                      | Pennsylvania. He is a member of the Institute of Chartered Accountants of India. He has been previously        |
|                      | associated with the Industrial Credit & Investment Corporation of India Limited (ICICI) and the merchant       |
|                      | banking division of Morgan Stanley (Private Equity).   |
| Dr. Rohit Manipal    | He is the Group – Chief Operating Officer of the company. He is associated with the company since March 28,    |
| Bhojraj              | 2020. He was previously associated with Infosys Technologies Limited, Novartis Healthcare Private Limited      |
|                      | and Genpact LLC. He holds a Bachelor of Medicine and Bachelor of Surgery ("MBBS") from the University of       |
|                      | Delhi. He holds a post-graduate diploma in management from the Indian Institute of Management,                 |
|                      | Ahmedabad. He has over 16 years of experience in diversified service industries including medical,             |
|                      | pharmaceuticals and IT industries.   |

Source: RHP, Arihant Capital Research

# **Financial Performance:**

| Consolidated Income Statement (INR<br>Mn) | 2019 | 2020 | 2021 |
|---|------|------|------|
| Revenue from Operations                   | 5428 | 7194 | 6500 |
| Other Income                              | 84   | 103  | 103  |
| Total Revenue                             | 5511 | 7297 | 6603 |
| Expenses:                                 |      |      |      |
| Employee Benefit                          | 857  | 1090 | 1021 |
| Finance Costs                             | 390  | 446  | 441  |
| Depreciation and Amortisation             | 603  | 694  | 733  |
| Medical Consumables/Pharmacy              | 802  | 1053 | 1033 |
| Other Expenses                            | 2283 | 3081 | 2819 |
| Total Expenses                            | 4936 | 6364 | 6046 |
| Profit Before Exeptional Items and Tax    | 575  | 934  | 557  |
| Total Tax Expense                         | 129  | 380  | 161  |
| Non-controlling interests                 | 0    | -4   | -5   |
| Profit After Tax                          | 446  | 557  | 400  |
| Basic EPS                                 | 4.83 | 5.98 | 4.36 |
| Diluted EPS                               | 4.74 | 5.92 | 4.25 |

| Consolidated Cash Flow Statement<br>(INR Mn)             | 2019  | 2020  | 2021 |
|--|-------|-------|------|
| Cash Flow From Operations                                | 1272  | 1704  | 1427 |
| Cash Flow From Investing Activities                      | -1169 | -1170 | -829 |
| Cash Flow From Financing Activities                      | -87   | -518  | -609 |
| Net Cash Generated during the period                     | 17    | 16    | -10  |
| Cash and Cash Equivalents at the beginning of the period | 35    | 51    | 67   |
| Cash and Cash Equivalents at the end of the period       | 51    | 67    | 57   |

Source: RHP, Arihant Capital Research

| Consolidated Balance Sheet (INR Mn)                  | 2019 | 2020  | 2021  |
|--|------|-------|-------|
| ASSETS   |      |       |       |
| Non-Current Assets                                   |      |       |       |
| Property, Plant and Equipment                        | 3614 | 3874  | 4277  |
| Right-of-use Asset                                   | 3565 | 3516  | 3689  |
| Goodwill   | 30   | 30    | 30    |
| Other Intangible assets                              | 35   | 23    | 15    |
| Financial Assets                                     | 351  | 471   | 627   |
| Income Tax Assets                                    | 40   | 22    | 45    |
| Deferred Tax Assets                                  | 180  | 3     | 28    |
| Other Non Current Assets                             | 120  | 227   | 131   |
| Total Non- Current Assets                            | 7935 | 8166  | 8842  |
| Current Assets                                       |      |       |       |
| Financial Assets excluding cash and cash equivalents | 1234 | 1845  | 1811  |
| Cash and Cash Equivalents                            | 51   | 67    | 57    |
| Other Current Assets                                 | 43   | 114   | 103   |
| Total Current Assets                                 | 1329 | 2026  | 1971  |
| TOTAL ASSETS   | 9264 | 10192 | 10813 |
| EQUITY AND LIABILITIES                               |      |       |       |
| Equity   |      |       |       |
| Equity Share Capital                                 | 549  | 549   | 549   |
| Other Equity   | 3172 | 3505  | 3915  |
| Non-controlling interest                             | 0    | 39    | 20    |
| Total Equity   | 3722 | 4093  | 4484  |
| Liabilities  |      |       |       |
| Non-Current Liabilities                              |      |       |       |
| Financial Liabilities                                | 4569 | 4675  | 5053  |
| Provisions   | 56   | 71    | 55    |
| Deferred tax liabilities (net)                       | 0    | 53    | 0     |
| Total Non- Current Liabilities                       | 4625 | 4800  | 5108  |
| Current Liabilities                                  |      |       |       |
| Financial liabilities                                | 768  | 1153  | 1064  |
| Other Current Liabilities                            | 90   | 102   | 94    |
| Provisions   | 8    | 8     | 25    |
| Income Tax Liabilties                                | 52   | 36    | 38    |
| Total Current Liabilities                            | 917  | 1300  | 1221  |
| TOTAL EQUITY AND LIABILITIES                         | 9264 | 10192 | 10813 |

### **Arihant Research Desk**

Email: instresearch@arihantcapital.com

Tel.: 022-42254800

| Head Office                            | Registered Office       |
|--|-------------------------|
| #1011, Solitaire Corporate Park        |                         |
| Building No. 10, 1 <sup>st</sup> Floor | Arihant House           |
| Andheri Ghatkopar Link Road            | E-5 Ratlam Kothi        |
| Chakala, Andheri (E)                   | Indore - 452003, (M.P.) |
| Mumbai – 400093                        | Tel: (91-731) 3016100   |
| Tel: (91-22) 42254800                  | Fax: (91-731) 3016199   |
| Fax: (91-22) 42254880                  |                         |

| Stock Rating Scale | Absolute Return |
|--------------------|-----------------|
| BUY                | >20%            |
| ACCUMULATE         | 12% to 20%      |
| HOLD               | 5% to 12%       |
| NEUTRAL            | -5% to 5%       |
| REDUCE             | -5% to -12%     |
| SELL               | <-12%           |

| Registration No. | Contact                 | Website                | Email Id                            |
|------------------|-------------------------|------------------------|-------------------------------------|
| INH000002764     | SMS: 'Arihant' to 56677 | www.arihantcapital.com | instresearch@arihantcapital.<br>com |

**Disclaimer:** This document has been prepared by Arihant Capital Markets Ltd. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Arihant may trade in investments, which are the subject of this document or in related investments and may have acted upon or used the information contained in this document or the research or the analysis on which it is based, before its publication. This is just a suggestion and Arihant will not be responsible for any profit or loss arising out of the decision taken by the reader of this document. Affiliates of Arihant may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. No matter contained in this document may be reproduced or copied without the consent of the firm.

Arihant Capital Markets Ltd. 1011, Solitaire Corporate park, Building No. 10, 1st Floor, Andheri Ghatkopar Link Road, Chakala, Andheri (E) Tel. 022-42254800Fax. 022-42254880